Sino Biopharmaceutical Ltd SMZ1
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 0.32
- Day Range
- HKD 0.32–0.34
- 52-Week Range
- HKD 0.29–1.17
- Bid/Ask
- HKD 0.00 / HKD 0.00
- Market Cap
- HKD 6.02 Bil
- Volume/Avg
- 34,450 / —
Key Statistics
- Price/Earnings (Normalized)
- 17.76
- Price/Sales
- 1.74
- Dividend Yield (Trailing)
- 1.87%
- Dividend Yield (Forward)
- 1.87%
- Total Yield
- 2.71%
Company Profile
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 25,806
- Website
- https://www.sinobiopharm.com
Competitors
Valuation
|
Metric
|
SMZ1
|
01093
|
VTRS
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.76 | 11.67 | 3.60 |
Price/Book Value | 1.55 | 2.22 | 0.60 |
Price/Sales | 1.74 | 2.33 | 0.80 |
Price/Cash Flow | 7.57 | 10.17 | 3.71 |
Price/Earnings
SMZ1
01093
VTRS
Financial Strength
|
Metric
|
SMZ1
|
01093
|
VTRS
|
|---|---|---|---|
Quick Ratio | 0.90 | 2.32 | 0.66 |
Current Ratio | 1.05 | 2.63 | 1.67 |
Interest Coverage | 11.55 | 276.31 | 1.15 |
Quick Ratio
SMZ1
01093
VTRS
Profitability
|
Metric
|
SMZ1
|
01093
|
VTRS
|
|---|---|---|---|
Return on Assets (Normalized) | 4.02% | 14.29% | 7.07% |
Return on Equity (Normalized) | 8.61% | 19.78% | 16.57% |
Return on Invested Capital (Normalized) | 5.53% | 17.91% | 9.85% |
Return on Assets
SMZ1
01093
VTRS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Zxdcvsf | Khlbmbq | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zxxmkdfz | Vdhswzn | $114.2 Bil | |||
| Moderna Inc
MRNA
| Pcngqknl | Gyxv | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Qmmfgkxl | Hwg | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kxbtgctf | Dtj | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jzcfjndv | Krljns | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zvjmpxfw | Pwdxt | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Bjtljyvs | Pbm | $12.8 Bil | |||
| Incyte Corp
INCY
| Vccsyglcz | Hjrjbb | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Vmhchxclb | Lxzgf | $12.2 Bil |